[{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italian Sarcoma Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Italian Sarcoma Group \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4t des Saarlandes","sponsor":"German High-Grade NHL Study Group | Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Universit\u00e4t des Saarlandes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4t des Saarlandes \/ German High-Grade NHL Study Group | Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4t des Saarlandes \/ German High-Grade NHL Study Group | Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Nanjing Luye Sike Pharmaceutical","sponsor":"Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi\u2019an Jiaotong ","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Nanjing Luye Sike Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing Luye Sike Pharmaceutical \/ Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi\u2019an Jiaotong ","highestDevelopmentStatusID":"10","companyTruncated":"Nanjing Luye Sike Pharmaceutical \/ Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi\u2019an Jiaotong "},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Funding","leadProduct":"Vincristine Sulfate","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Birmingham \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Birmingham \/ Undisclosed"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NanoAlvand \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"National Cancer Institute | Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wake Forest University Health Sciences \/ National Cancer Institute | Spectrum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ National Cancer Institute | Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"TACL Consortium \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Seagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Vincristine Sulfate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Study Phase : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Vicrista (vincristine sulphate) is a type of chemotherapy called a vinca alkaloid which interfere with microtubules and blocks cell growth by stopping mitosis. It is indicated for pediatric cancers.

                          Product Name : Vicrista

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          November 03, 2024

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          NanoAlvand

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary tec...

                          Product Name : Adcetris

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          November 11, 2022

                          Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Birmingham

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Birmingham

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : The ten year SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) is a Phase III clinical trial designed to evaluate potential treatment pathways for children identified with the disease.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          May 21, 2020

                          Lead Product(s) : Vincristine Sulfate,Carboplatin,Etoposide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : $0.7 million

                          Deal Type : Funding

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Vincristine Sulfate is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Diseases.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 28, 2020

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Axis Clinicals Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          TACL Consortium

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          TACL Consortium

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Marqibo (Vincristine Sulfate) is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Marqibo

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          August 26, 2016

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Spectrum Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Wake Forest University Health Sciences

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Wake Forest University Health Sciences

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Vincristine Sulfate is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 13, 2015

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : National Cancer Institute | Spectrum Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Nanjing Luye Sike Pharmaceutical

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Nanjing Luye Sike Pharmaceutical

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi’an Jiaotong

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Vincristine Sulfate is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 27, 2014

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi’an Jiaotong

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Italian Sarcoma Group

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Italian Sarcoma Group

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Vincristine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sarcoma, Ewing.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 14, 2014

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Vincristine Sulfate is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          May 10, 2013

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Universität des Saarlandes

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Universität des Saarlandes

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Vincristine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 23, 2011

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : German High-Grade NHL Study Group | Spectrum Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank